Akriderm, 0.05% ointment 30 g

Pharmgroup:

Glucocorticosteroid for topical use.

Pharm Action:

The corticosteroid betamethasone dipropionate has anti-inflammatory, anti-allergic, anti-exudative, anti-edema and antipruritic effects.

Inhibits leukocyte accumulation, release of lysosomal enzymes and anti-inflammatory mediators in the inflammation focus, inhibits phagocytosis, reduces vascular and tissue permeability and prevents formation of inflammatory edema.

Indications

Active ingredient

Composition

1 g:

– betamethasone dipropionate 0.64 mg;

excipients:

propylparahydroxybenzoate,

vaseline oil,

isopropyl myristate,

vaseline.

How to take, the dosage

Externally. Acriderm® is applied thinly to the affected area of the skin twice a day in the morning and evening.

A different frequency of use can be determined by the doctor based on the severity of the disease. In mild cases, once a day is usually enough; more frequent use might be necessary.

The duration of treatment depends on the effectiveness and tolerability of the therapy and is 2-4 weeks.

If clinical improvement does not occur, the diagnosis needs to be clarified.

Interaction

Acriderm does not interact with other medicines.

Directions for use

Special Instructions

If there are signs of hypersensitivity or skin irritation associated with the use of the drug, treatment should be discontinued and the patient should find an adequate therapy. During prolonged treatment, when applying the drug to large surfaces of the skin, when using occlusive dressings, as well as in children, systemic absorption of glucocorticosteroids is possible.

In children from 1 year of age the drug is prescribed only with strict indications and under medical supervision because of possible systemic side effects associated with betamethasone.

When the drug is used on large surfaces and/or under an occlusive dressing suppression of hypothalamic-pituitary-adrenal system function and development of hypercorticism symptoms may occur, reduction of growth hormone excretion and increased intracranial pressure may be observed.

Atrophic changes may occur on the skin of the face more frequently than on other body surfaces after long-term treatment with topical glucocorticosteroids; in this case, the course of treatment should not exceed 5 days.

Acriderm® cream is not suitable for use in ophthalmology. Avoid getting the drug in the eyes.
If the drug is used for a long time it should be withdrawn gradually.

Contraindications

Hypersensitivity to any of the ingredients of the drug, bacterial, fungal skin diseases, skin tuberculosis, cutaneous manifestations of syphilis, varicella, herpes simplex, skin postvaccinal reactions, open wounds, trophic ulcers of the shin, rosacea, acne vulgaris, skin cancer, nevi, atheroma, melanoma, hemangioma, xanthoma, sarcoma, lactation period and children under 1 year old.

With caution

Pregnancy.

In long-term use or application to large surfaces: cataracts, diabetes, glaucoma, tuberculosis.

Side effects

When using glucocorticosteroids topically there may be: burning, irritation, dry skin, folliculitis, hypertrichosis, acne-like rashes, skin itching, stretch marks, sweating, hypopigmentation, perioral dermatitis.

Long-term use or use of occlusive dressings causes skin maceration, secondary infection, skin atrophy, sweating, purpura, local hirsutism and telangiectasia.

When applied to large body surfaces, mainly in children systemic side effects of glucocorticosteroids may occur (gastritis, ulceration of mucosa of the gastrointestinal tract, hyperglycemia, glucosuria, reversible suppression of adrenal cortical function, manifestation of Cushing’s syndrome).

In case of any adverse reactions not described in the instructions, consult a physician.

Overdose

Acute overdose is unlikely; however, with excessive or prolonged use of the drug, chronic overdose is possible, accompanied by signs of hypercorticism: hyperglycemia, glucosuria, reversible suppression of adrenal cortical function, manifestation of Cushing’s syndrome.

Treatment. Appropriate symptomatic treatment is indicated. In case of chronic toxic effects, gradual withdrawal of the drug is recommended.

Similarities